Alethea Capital Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-446,127
| Closed | -$32.2M | – | 16 |
|
|
2025
Q4 | $32.2M | Hold |
446,127
| – | – | 15.62% | 2 |
|
|
2025
Q3 | $19.4M | Buy |
446,127
+17,503
| +4% | +$708K | 12.49% | 3 |
|
|
2025
Q2 | $12.2M | Buy |
428,624
+6,900
| +2% | +$206K | 9.21% | 3 |
|
|
2025
Q1 | $12.4M | Buy |
421,724
+853
| +0.2% | +$26.6K | 9.29% | 3 |
|
|
2024
Q4 | $12.2M | Sell |
420,871
-6,583
| -2% | -$275K | 10.48% | 3 |
|
|
2024
Q3 | $19.6M | Sell |
427,454
-76,050
| -15% | -$3.3M | 14.18% | 3 |
|
|
2024
Q2 | $20.6M | Sell |
503,504
-257,193
| -34% | -$7.38M | 15.61% | 3 |
|
|
2024
Q1 | $19.4M | Sell |
760,697
-93,954
| -11% | -$1.47M | 15.77% | 3 |
|
|
2023
Q4 | $7.73M | Hold |
854,651
| – | – | 8.92% | 2 |
|
|
2023
Q3 | $5.45M | Buy |
854,651
+5,000
| +0.6% | +$43.1K | 6.7% | 2 |
|
|
2023
Q2 | $9.42M | Hold |
849,651
| – | – | 10.08% | 2 |
|
|
2023
Q1 | $13M | Buy |
849,651
+24,178
| +3% | +$532K | 13.77% | 2 |
|
|
2022
Q4 | $18.3M | Sell |
825,473
-10,000
| -1% | -$149K | 17.56% | 2 |
|
|
2022
Q3 | $13.6M | Hold |
835,473
| – | – | 17.24% | 2 |
|
|
2022
Q2 | $12.1M | Sell |
835,473
-54,484
| -6% | -$811K | 15.2% | 2 |
|
|
2022
Q1 | $16.4M | Buy |
889,957
+420
| +0% | +$7.13K | 14.87% | 2 |
|
|
2021
Q4 | $21.1M | Sell |
889,537
-18,030
| -2% | -$431K | 17.94% | 2 |
|
|
2021
Q3 | $22.4M | Sell |
907,567
-259,180
| -22% | -$5.63M | 19.68% | 2 |
|
|
2021
Q2 | $28.8M | Sell |
1,166,747
-219,117
| -16% | -$5.1M | 18.14% | 2 |
|
|
2021
Q1 | $30.2M | Sell |
1,385,864
-185,296
| -12% | -$4.54M | 18.44% | 2 |
|
|
2020
Q4 | $40.1M | Buy |
+1,571,160
| New | +$45.8M | 20.1% | 2 |
|
Other funds holding RNAM
Alethea Capital Management's RNAM Position: Q1 2026 in Review
Alethea Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 446,127 shares — an estimated $32.2M sold.
Alethea Capital Management first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $40.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Alethea Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Alethea Capital Management sold 446,127 Avidity Biosciences shares in Q1 2026, an estimated $32.2M.
- Alethea Capital Management first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- Alethea Capital Management's Avidity Biosciences position peaked at $40.1M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.